L 870810

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596717

CAS#: 410544-95-5

Description: L 870810 is a small-molecule inhibitor of HIV-1 integrase with potent antiviral activity in cell culture and good pharmacokinetic properties, has an 8-hydroxy-(1,6)-naphthyridine-7-carboxamide pharmacophore.


Chemical Structure

img
L 870810
CAS# 410544-95-5

Theoretical Analysis

MedKoo Cat#: 596717
Name: L 870810
CAS#: 410544-95-5
Chemical Formula: C20H19FN4O4S
Exact Mass: 430.1111
Molecular Weight: 430.45
Elemental Analysis: C, 55.81; H, 4.45; F, 4.41; N, 13.02; O, 14.87; S, 7.45

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L 870810; L-870810; L870810; L-870,810; L 870,810; L870,810;

IUPAC/Chemical Name: 5-(1,1-dioxido-1,2-thiazinan-2-yl)-N-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide

InChi Key: DIDKWCOCQJWMDJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H19FN4O4S/c21-14-7-5-13(6-8-14)12-23-20(27)17-18(26)16-15(4-3-9-22-16)19(24-17)25-10-1-2-11-30(25,28)29/h3-9,26H,1-2,10-12H2,(H,23,27)

SMILES Code: O=C(C1=NC(N(CCCC2)S2(=O)=O)=C3C=CC=NC3=C1O)NCC4=CC=C(F)C=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 430.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Markopoulos C, Vertzoni M, Symillides M, Kesisoglou F, Reppas C. Two-Stage Single-Compartment Models to Evaluate Dissolution in the Lower Intestine. J Pharm Sci. 2015 Sep;104(9):2986-97. doi: 10.1002/jps.24485. Epub 2015 May 18. PubMed PMID: 25989323.

2: Petrakis O, Vertzoni M, Angelou A, Kesisoglou F, Bentz K, Goumas K, Reppas C. Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example. J Pharm Pharmacol. 2015 Jan;67(1):56-67. doi: 10.1111/jphp.12320. Epub 2014 Sep 23. PubMed PMID: 25252222.

3: Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, Zheng YT, Ding J, Neamati N, Long YQ. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J Med Chem. 2012 Nov 26;55(22):9492-509. doi: 10.1021/jm300667v. Epub 2012 Nov 7. PubMed PMID: 23098137.

4: Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M, Markowitz M. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother. 2009 Oct;53(10):4275-82. doi: 10.1128/AAC.00397-09. Epub 2009 Aug 3. PubMed PMID: 19651917; PubMed Central PMCID: PMC2764199.

5: Barreca ML, Iraci N, De Luca L, Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem. 2009 Sep;4(9):1446-56. doi: 10.1002/cmdc.200900166. PubMed PMID: 19544345.

6: Garvey EP, Schwartz B, Gartland MJ, Lang S, Halsey W, Sathe G, Carter HL 3rd, Weaver KL. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant. Biochemistry. 2009 Feb 24;48(7):1644-53. doi: 10.1021/bi802141y. PubMed PMID: 19178153.

7: Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, Kodama M, Endoh T, Oosugi E, Matsushita Y, Murai H, Fujishita T, Yoshinaga T, Garvey E, Foster S, Underwood M, Johns B, Sato A, Fujiwara T. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008 Nov;80(2):213-22. doi: 10.1016/j.antiviral.2008.06.012. Epub 2008 Jul 14. PubMed PMID: 18625269.

8: Zahm JA, Bera S, Pandey KK, Vora A, Stillmock K, Hazuda D, Grandgenett DP. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob Agents Chemother. 2008 Sep;52(9):3358-68. doi: 10.1128/AAC.00271-08. Epub 2008 Jun 30. PubMed PMID: 18591263; PubMed Central PMCID: PMC2533447.

9: Hombrouck A, Van Remoortel B, Michiels M, Noppe W, Christ F, Eneroth A, Sahlberg BL, Benkestock K, Vrang L, Johansson NG, Barreca ML, De Luca L, Ferro S, Chimirri A, Debyser Z, Witvrouw M. Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrob Agents Chemother. 2008 Aug;52(8):2861-9. doi: 10.1128/AAC.00210-08. Epub 2008 Jun 9. PubMed PMID: 18541726; PubMed Central PMCID: PMC2493095.

10: Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, Witvrouw M. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother. 2008 Jun;52(6):2069-78. doi: 10.1128/AAC.00911-07. Epub 2008 Mar 31. PubMed PMID: 18378713; PubMed Central PMCID: PMC2415791.

11: Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74. Epub 2007 Oct 31. PubMed PMID: 17977962; PubMed Central PMCID: PMC2224569.

12: Savarino A, Pistello M, D'Ostilio D, Zabogli E, Taglia F, Mancini F, Ferro S, Matteucci D, De Luca L, Barreca ML, Ciervo A, Chimirri A, Ciccozzi M, Bendinelli M. Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology. 2007 Oct 30;4:79. PubMed PMID: 17971219; PubMed Central PMCID: PMC2244644.

13: Pandey KK, Bera S, Zahm J, Vora A, Stillmock K, Hazuda D, Grandgenett DP. Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J Virol. 2007 Nov;81(22):12189-99. Epub 2007 Sep 5. PubMed PMID: 17804497; PubMed Central PMCID: PMC2169005.

14: Egbertson MS. HIV integrase inhibitors: from diketoacids to heterocyclic templates: a history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM). Curr Top Med Chem. 2007;7(13):1251-72. Review. PubMed PMID: 17627556.

15: Nair V, Chi G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev Med Virol. 2007 Jul-Aug;17(4):277-95. Review. PubMed PMID: 17503547.

16: Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68. Review. PubMed PMID: 17472411.

17: Daelemans D, Lu R, De Clercq E, Engelman A. Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. J Virol. 2007 Apr;81(8):4381-5. Epub 2007 Feb 7. PubMed PMID: 17287285; PubMed Central PMCID: PMC1866133.

18: Jin H, Cai RZ, Schacherer L, Jabri S, Tsiang M, Fardis M, Chen X, Chen JM, Kim CU. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors. Bioorg Med Chem Lett. 2006 Aug 1;16(15):3989-92. Epub 2006 May 24. PubMed PMID: 16723225.

19: Dayam R, Sanchez T, Neamati N. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. J Med Chem. 2005 Dec 15;48(25):8009-15. PubMed PMID: 16335925.

20: Reeves JD, Piefer AJ. Emerging drug targets for antiretroviral therapy. Drugs. 2005;65(13):1747-66. Review. PubMed PMID: 16114975.